- Stoke Therapeutics shares gain 78% after test results
- Morgan Stanley boosts sentiment around Seagate shares
Wall Street indices started Tuesday's trading session slightly higher, with investors attempting to resume the rally that drove stocks to record highs after falling in the previous session. At this point, the S&P500 is gaining 0.22%, the Nasdaq is adding 0.4% and the Russell 2000 is adding 0.78%.
إبدأ بالإستثمار اليوم أو تدرّب على حساب تجريبي
إنشاء حساب حساب تجريبي تحميل تطبيق الجوال تحميل تطبيق الجوالSource: xStation5
The US2000 index is gaining nearly 0.33% at the start of Tuesday's trading session, holding the psychological barrier of 2,100 points. Maintaining this zone could be key to maintaining the overall uptrend. A drop below, on the other hand, could initiate a downward correction. A possible zone of possible restriction could be the area of the 50% Fibo of the 2021 decline wave and the 50-day exponential moving average (blue curve).Source: xStation
News
Stoke Therapeutics (STOK.US) shares are up 78% today after the company announced that data from a study of the STK-001 treatment for Dravet syndrome showed significant effects in reducing seizures.
Seagate (STX.US) is up 4% after Morgan Stanley raised its recommendation on the company's stock to "outperform," predicting a period of "structurally stronger gross margins."
Krispy Kreme shares jumped 15% after the announcement that the company's doughnuts will be sold in McDonald's (MCD.US) restaurants across the United States.
Analyst action
- Wedbush raises its target price for Microsoft (MSFT.US) shares to $500 from $475, citing the transformative impact of AI, which is expected to change the Cloud division's growth trajectory in the coming years.
- JPMorgan raises its target price for Stoke Therapeutics (STOK.US) shares to $13 from $6 after encouraging results from the first phase of the dravet treatment.
